Charles River Labs Intl Stock
Price
Target price
€214.50
€214.50
-4.110%
-9.2
-4.110%
€247.61
18:51 / Tradegate
WKN: 939391 / Symbol: CRL / Name: Charles River Lb / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Charles River Labs Intl Stock
Charles River Labs Intl took a tumble today and lost -€9.200 (-4.110%).
Charles River Labs Intl is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 247 € there is a slightly positive potential of 15.15% for Charles River Labs Intl compared to the current price of 214.5 €.
Pros and Cons of Charles River Labs Intl in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
S********** s********
Cons
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Charles River Labs Intl vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Charles River Labs Intl | -4.110% | 3.757% | -11.160% | 21.181% | 5.023% | -18.358% | - |
| Novocure Ltd | -3.160% | -0.177% | -7.436% | -80.306% | -21.086% | -93.202% | - |
| Sage Therapeutics Inc. | -1.830% | 2.673% | -32.022% | -71.991% | -39.500% | -80.824% | - |
| Iovance Biotherapeutics Inc. | -2.150% | -1.220% | -21.423% | 111.904% | 39.985% | -57.701% | - |
Comments
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Evercore ISI from $260.00 to $265.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at UBS Group AG from $270.00 to $290.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
Charles River Laboratories International, Inc. (NYSE: CRL) had its price target raised by analysts at Robert W. Baird from $252.00 to $268.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for CRL provided by MarketBeat
News
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories International, Inc. (NYSE: CRL) today announced it has reached 100 percent renewable electricity across all of its global sites as of the first quarter of 2024
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it is launching its Alternative Methods Advancement Project (AMAP), an initiative dedicated to developing
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
Charles River Laboratories International, Inc. (NYSE: CRL) will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to